Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Phase 2b data show olorofim has activity and acceptable tolerability in patients with invasive fungal disease and limited options, including azole‑resistant Aspergillus and intrinsically resistant moulds, supporting further controlled studi
This study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.
PRIMAVERA immunobridging shows single-dose Cervarix induces near-universal seropositivity at 36 months and non-inferior HPV-18 antibodies versus three-dose Gardasil-4, but HPV-16 antibody GMCs were lower; results inform but do not yet suppo
In a multicentre test‑negative study of 1006 adults aged 75–79 in England, a bivalent RSV pre‑F vaccine reduced RSV‑associated hospitalisation by 82% overall and protected against severe disease and exacerbations of chronic heart and lung d
A randomized trial in India found no superiority of oral voriconazole over itraconazole for chronic pulmonary aspergillosis at 6 months; efficacy was similar, but voriconazole caused more adverse events.
The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse even
Two randomized trials from Pemba Island show orodispersible ivermectin–albendazole yields dose‑dependent high cure rates in preschool children, and moxidectin–albendazole is superior to albendazole alone in school‑aged children, both with a
A pooled individual‑patient meta‑analysis (6056 participants) shows single low‑dose primaquine (0.25 mg/kg) added to ACTs reduces gametocyte carriage and mosquito infectivity across ages and transmission settings without increasing clinical
This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan
An international Delphi consensus defined a Core Outcome Measurement Set (COMS) for dengue trials to harmonise outcome selection and measurement across settings, improving comparability and evidence synthesis.
Phase 2 PLATCOV results show oral ensitrelvir accelerates SARS‑CoV‑2 clearance versus no drug and has antiviral effects close to ritonavir‑boosted nirmatrelvir, supporting further phase 3 evaluation.
This review synthesizes evidence from Rwanda’s 2024 Marburg virus disease outbreak, highlighting epidemiologic characteristics, clinical presentations, investigational therapeutics, and vaccine deployment strategies that contributed t
An 18‑month booster of the VLA15 Lyme vaccine candidate produced strong anamnestic anti‑OspA IgG responses exceeding primary‑series levels in children, adolescents, and adults, with a tolerability profile similar to primary doses.
This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies an
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation o
A post-hoc analysis of the BALANCE randomized trial shows that after accounting for treatment non-adherence using causal inference methods, 7 days of antibiotics for uncomplicated non‑Staphylococcus aureus bloodstream infection remains non‑
A nationally representative serosurvey and transmission modelling study in Bangladesh estimates low population-level JEV exposure but large numbers of infections annually; spatially targeted vaccination would be most efficient, though not c
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig
A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited react
This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the c
Open language-specific specialty feeds and department pages.